drugset / Trial / NCT06140836
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Phase 3
Active not recruiting
190 enrolled
Bristol-Myers Squibb
Zai Lab (Shanghai) Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2023-12-21
- Primary completion
- 2026-03-13
- Completion
- 2027-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Crizotinib | Small molecule | — | — |
| Subject | Repotrectinib | Small molecule | — | — |